CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-08 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −1,500 | 229,854 | ||
| 2021-09-27 | Mills Kenneth T. President and CEO | Option exercise | +1,500 | $3.76 | $6K | 282,484 |
| 2021-09-27 | Mills Kenneth T. President and CEO | Sale | −1,500 | $42.19 | $63K | 280,984 |
| 2021-09-27 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −1,500 | 231,354 | ||
| 2021-09-17 | Fox Allan M. Director | Sale | −48,233 | $45.04 | $2.2M | 1,364,309 |
| 2021-09-14 | Mills Kenneth T. President and CEO | Option exercise | +33,146 | $3.76 | $125K | 314,130 |
| 2021-09-14 | Mills Kenneth T. President and CEO | Option exercise | +1,854 | $0.85 | $2K | 315,984 |
| 2021-09-14 | Mills Kenneth T. President and CEO | Sale | −35,000 | $45.11 | $1.6M | 280,984 |
| 2021-09-14 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −33,146 | 232,854 | ||
| 2021-09-14 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −1,854 | 37,816 | ||
| 2021-09-13 | Mills Kenneth T. President and CEO | Option exercise | +3,000 | $3.76 | $11K | 283,984 |
| 2021-09-13 | Mills Kenneth T. President and CEO | Sale | −3,000 | $40.02 | $120K | 280,984 |
| 2021-09-13 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −3,000 | 266,000 | ||
| 2021-09-03 | MIGAUSKY GEORGE V Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-09-03 | Bennett Jean Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-07-27 | Vasista Vittal Chief Financial Officer | Option exercise | +10,000 | $0.85 | $9K | 123,640 |
| 2021-07-27 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −10,000 | 64,900 | ||
| 2021-06-30 | Danos Olivier Chief Scientific Officer | Grant or award | +555 | $33.02 | $18K | 19,598 |
| 2021-06-25 | Mills Kenneth T. President and CEO | Option exercise | +1,500 | $3.76 | $6K | 282,484 |
| 2021-06-25 | Mills Kenneth T. President and CEO | Sale | −1,500 | $40.25 | $60K | 280,984 |
Page 16 of 25 · 494 trades